Predicting Early Mortality Among Implantable Defibrillator Patients Treated With Cardiac Resynchronization Therapy by Theuns, D.A.M.J. (Dominic) et al.
ARTICLE IN PRESS
Journal of Cardiac Failure Vol. 00 No. 00 2019Predicting Early Mortality Among Implantable Defibrillator
Patients Treated With Cardiac Resynchronization TherapyDOMINIC A.M.J. THEUNS, PhD,1 NICK VAN BOVEN, MD, PhD,1,2 BEAT A. SCHAER, MD,3 TIM HESSELINK, MD,4
MAXIMO RIVERO-AYERZA, MD, PhD,5 VICTOR UMANS, MD, PhD, FACC,2 CHRISTIAN STICHERLING, MD,3
MARCOEN F. SCHOLTEN, MD, PhD,4 FREDERIK VERBRUGGE, MD,5 AND FELIX ZIJLSTRA, MD, PhD1















https://doi.org/1Background: The beneficial effects of a cardiac resynchronization defibrillator (CRT-D) in patients with
heart failure, low left ventricular ejection fraction (LVEF), and wide QRS have clearly been established.
Nevertheless, mortality remains high in some patients. The aim of this study was to develop and validate a
risk score to identify patients at high risk for early mortality who are implanted with a CRT-D.
Methods and Results: For predictive modelling, 1282 consecutive patients from 5 centers (74% male;
median age 66 years; median LVEF 25%; New York Heart Association class IIIIV 60%; median QRS-width
160 ms) were randomly divided into a derivation and validation cohort. The primary endpoint is mortality at
3 years. Model development was performed using multivariate logistic regression by checking log likelihood,
Akaike information criterion, and Bayesian information criterion. Model performance was validated using C
statistics and calibration plots. The risk score included 7 independent mortality predictors, including myocar-
dial infarction, LVEF, QRS duration, chronic obstructive pulmonary disease, chronic kidney disease, hypona-
tremia, and anemia. Calibration-in-the-large was suboptimal, reflected by a lower observed mortality (44%)
than predicted (50%). The validated C statistic was 0.71 indicating modest performance.
Conclusion: A risk score based on routine, readily available clinical variables can assist in identifying
patients at high risk for early mortality within 3 years after CRT-D implantation. (J Cardiac Fail
2019;00:17)
Key Words: Heart failure, mortality, risk modeling, cardiac resynchronization therapy, implantable cardi-
overter-defibrillator.Heart failure (HF) is a progressive disease associated with
high morbidity and mortality. The prevalence of HF is increas-
ing and the associated costs are rising.1,2 Data from randomized
and observational studies have shown the beneficial effect of
cardiac resynchronization therapy (CRT) in selected patients
with drug refractory HF, reduced left ventricular ejection frac-
tion (LVEF), and electrical dyssynchrony: it improves clinical
symptoms, reduces hospitalizations, and lowers mortality in a
considerable proportion of patients.36 In addition, HF patients
with low LVEF are at increased risk for arrhythmic death.artment of Cardiology, Erasmus MC, Rotterdam, the
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1Prophylactic implantable cardioverter-defibrillator (ICD)
implantation is indicated for patients with ischemic or non-
ischemic cardiomyopathy and LVEF 35%.79 Theoretically,
all patients with HF and left ventricular dysfunction who meet
the indication criteria for CRT also qualify to have an ICD for
primary prevention of sudden cardiac death. Consequently,
ICDs combined with CRT (CRT-D) are part of the standard
management of HF patients with reduced LVEF.10,11 However,
given the heterogeneity in mortality risk among HF patients
and the fact that only a minority of patients will experience
ventricular arrhythmias, appropriate risk prediction is of para-
mount importance in maximizing the survival benefit conferred
by the CRT-D.12 Several models have been developed to pre-
dict mortality risk in HF patients such as the Seattle Heart Fail-
ure Model (SHFM) and the Heart Failure Survival Score.13,14
Despite the fact that the SHFM takes the eventual use of device
therapy, such as an ICD or CRT, into account, the model was
not designed for HF patients who already had a device
implanted. Recently, a clinical risk score was developed to pre-
dict CRT response, which also appeared to have reasonable
discriminative power to predict survival.15 However, risk esti-
mation models to predict early mortality in HF patients follow-
ing CRT-D implantation are scarce. Therefore, the purpose of
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early mortality in primary prevention CRT-D patients.
Methods
Study Population
We used data from prospective ICD registries of the car-
diology departments of Erasmus MC (Rotterdam, the Neth-
erlands), the University Hospital of Basel (Basel,
Switzerland), Ziekenhuis Oost-Limburg (Genk, Belgium),
Noordwest Ziekenhuisgroep (Alkmaar, the Netherlands),
and Medisch Spect Twente (Enschede, the Netherlands).
From these registries, all patients (n = 1282) who received a
first implantation of a CRT-D device for the primary pre-
vention of sudden cardiac death between January 1, 2000
and October 31, 2013 were identified.
This retrospective study was not subjected to the Dutch
Medical Research Involving Human Subjects Act and the
need for written informed consent was waived. The study
was carried out according to the ethical principles for medi-
cal research involving human subjects established by the
Declaration of Helsinki. The privacy of all patients and the
confidentiality of their personal information were protected.
Data Collection, Variable Definitions, and Clinical
Endpoint
Potential candidate variables associated with mortality in
HF were identified based on review of the literature, clinical
relevance, and their routine availability. They included
demographic characteristics, clinical presentation, labora-
tory data, and preexisting comorbid conditions.
Demographics, clinical data, and medical therapy prior to
CRT-D implantation were obtained for all patients by search-
ing the health records of the hospital. If multiple laboratory
data were available, values from the date closest to the date
of implantation were used; all laboratory values obtained up
to 7 days prior to CRT-D implantation were accepted.
Diabetes mellitus was defined as HbA1c>6.5% or the use
of oral hypoglycemic agents or use of parenteral insulin;
anemia as a serum hemoglobin concentration of <12 g/dL
(female) or <13 g/dL (male). The glomerular filtration rate
(GFR) was estimated with the formula of Modified Diet in
Renal Disease.16 Renal function was stratified according to
the KDIGO/KDOQ stages for chronic kidney disease
(CKD): stage 1, ie, 90 mL/min/1.73 m2; stage 2, ie,
6089 mL/min/1.73 m2; stage 3, ie, <60 mL/min/1.73 m2
and stage 4, ie, <30 mL/min/1.73 m2.17 Presence of CKD
was defined as GFR <60 mL/min/1.73 m2. Hyponatremia
was defined as serum sodium level <136 mmol/L.
The clinical endpoint for this study was all-cause mortal-
ity; patients who underwent cardiac transplantation were
censored at the day of transplantation.
Statistical Analysis
For the purpose of this study, one-half of the patients were
randomly selected by use of random integer assignment toform the derivation cohort, and the remainder formed the val-
idation cohort. Summary baseline data are presented as
median with 25th and 75th percentiles, and categorical data
are presented as percentages and counts. Data were com-
pared by the KruskalWallis H test and chi-square test as
appropriate. Although most patients had a relatively com-
plete dataset, variables with >5% of missing data were
excluded from analysis (body mass index, diastolic and sys-
tolic blood pressure, and baseline heart rate). The method of
multiple imputation was used to include variables with <5%
of missing data in model selection and regression analysis.
Candidate variables in the derivation cohort that were
associated with mortality on univariate analysis (P  .1)
were included as covariates in a series of multivariate
binary logistic regression models for further analysis. The
goodness of fit was evaluated by calculating the likelihood
ratio (LR), Akaike information criterion (AIC), and Bayes-
ian information criterion (BIC). A higher LR and lower
AIC and BIC suggest better goodness of fit.
Discrimination of the final prediction model was assessed
by the use of the Harrell C statistic. Model discrimination
was deemed poor if the C statistic was between 0.50 and
0.70, modest between 0.70 and 0.80, and good if >0.80. To
assess the prognostic value of the risk score, the population
was stratified into quintiles of the continuous risk score.
Model calibration was visualized by plotting the predicted
risks against the observed risks in a calibration plot, and fur-
ther described by the calibration slope (ideally equal to 1)
and intercept (ideally equal to 0).18 As a measure of accu-
racy, the Brier score was calculated, which is the averaged
squared difference between predicted and observed values.
The Brier score ranges from 0 to 1; lower scores being bet-
ter, a 0 indicates a perfect model. Usually, a model is con-
sidered useful if the Brier score is <0.25.
Cumulative mortality rates were calculated according to
the KaplanMeier method and differences between groups
compared with the log rank test. Statistical analysis was
performed using STATA v11 SE for Windows (StataCorp,
College Station, TX) and R statistical software, v3.5.3. Sta-
tistical significance was defined as P < .05 (two-tailed).
Results
Description of the Derivation and Validation Cohorts
The study included 1282 patients with a median follow-
up of 3.4 years (1.85.4 years). After random assignment,
the derivation cohort consisted of 639 patients and the vali-
dation cohort of 643 patients (N = 1282 patients). The
median follow-up was not different between the derivation
and validation cohort (P = .99). Demographics and clinical
characteristics of both cohorts are presented in Table 1. The
derivation and validation cohort were similar with respect
to age, gender, etiology of heart failure, comorbid condi-
tions, laboratory values, and medical treatment. The major-
ity of CRT-D recipients were men (76%) with a median age
of 66 years. Ischemic etiology of heart failure was present
in 50% of the patients.
Table 1. Clinical Characteristics of the Derivation and Validation Cohorts
Derivation Cohort (n = 639) Validation Cohort (n = 643) P Value
Demographics
Age, y 67 (5873) 66 (5972) .95
Male gender 483 (76%) 469 (73%) .31
Clinical characteristics
NYHA class IIIIV 372 (58%) 374 (58%) .91
Ejection fraction, % 24 (2030) 25 (2030) .40
Ischemic etiology 313 (49%) 326 (51%) .64
QRS duration, ms 160 (140180) 160 (140177) .07
Comorbid condition
Atrial fibrillation 128 (20%) 139 (22%) .54
Diabetes mellitus 163 (26%) 169 (26%) .75
Cerebrovascular disease 54 (8%) 72 (11%) .11
Chronic obstructive pulmonary disease 93 (15%) 83 (13%) .42
Renal failure 254 (40%) 254 (40%) .91
Laboratory values
Hemoglobin, g/dL 13.7 (12.414.7) 13.9 (12.714.9) .05
Serum sodium, mmol/L 140 (137142) 140 (137142) .79
Serum BUN, mg/dL 8.3 (6.411.7) 8.1 (6.110.9) .16
Serum creatinine, mg/dL 1.1 (0.91.4) 1.1 (0.91.4) .23
Medications
ACE inhibitor 481 (75%) 476 (74%) .65
Angiotensin receptor blocker 152 (24%) 160 (25%) .65
Amiodarone 82 (13%) 81 (13%) .93
Beta-blocker 521 (82%) 528 (82%) .83
Digoxin 104 (16%) 127 (20%) .11
Diuretic 513 (80%) 513 (80%) .82
Aldosterone antagonist 309 (48%) 284 (44%) .15
Allopurinol 48 (8%) 55 (9%) .54
Statin 350 (55%) 390 (61%) .04
Continuous data are presented as median (interquartile range). Categorical data are presented as n(%).
ACE, angiotensin converting enzyme; BUN, blood urea nitrogen; NYHA, New York Heart Association.
Table 2. Univariate Logistic Regression Analysis
Variable OR (95% CI) P Value
Age (10 years) 1.26 (1.001.57) .051
Male gender 1.30 (0.752.26) .35
AF 1.11 (0.641.93) .70
MI 2.12 (1.353.34) .001
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16.5%, at 1 and 3 years, respectively. In the derivation cohort
(n = 639), 1- and 3-year mortality was 5.0% and 15.9%. In
the validation cohort (n = 643), 1- and 3-year mortality was
6.4% and 17.0%. The mortality rates were not different
between the derivation and the validation cohort (P = .64).LVEF 25% 1.79 (1.082.94) .023
LVEF (5% decrease)* 1.31 (1.101.55) .002
NYHA 34 2.06 (1.243.40) .005
QRS 150 ms 0.58 (0.370.93) .022
DM 1.83 (1.142.95) .013
COPD 1.93 (1.103.36) .021
CVA 1.28 (0.602.72) .52
Hyponatremiay 3.47 (1.996.05) <.001
GFR (per 15 mL/min)z 1.84 (1.402.41) <.001
CKDǁ 3.12 (1.954.98) <.001
Anemia{ 2.17 (1.373.43) .001
AF, atrial fibrillation; CVA, cerebrovascular accident incl. transient
ischemic attack; DM, diabetes mellitus.
*LVEF per 5% decrease in patients with LVEF 35%.
yHyponatremia defined as serum sodium <136 mmol/L.
zGFR per 15 mL/min decrease in patients with GFR<60 mL/min/1.73 m2.
ǁCKD defined as GFR <60 mL/min/1.73 m2.
{Anemia defined as serum hemoglobin < 12 g/dL (female) or
< 13 g/dL (male).Predictors of Mortality
Univariate logistic regression analysis was performed
to identify variables associated with mortality (Table 2).
We found that age, the presence of myocardial infarction
(MI), diabetes mellitus, LVEF, New York Heart Associa-
tion (NYHA) III-IV, chronic obstructive pulmonary dis-
ease (COPD), CKD, hyponatremia, and anemia were all
associated with a higher risk of mortality at 3 years fol-
low-up. In addition, QRS 150 ms was associated with a
lower risk of mortality. In Table 3, the b-coefficients for
the variables and AIC, BIC, and C statistic for successive
models are presented. Model 1 included age (per decade)
as continuous variable and LVEF 25%, MI, COPD,
CKD, hyponatremia, anemia, and QRS duration 150 ms
as dichotomous variables. Model 1 performed fairly well
in goodness of fit and discrimination. In Model 2, LVEF
as dichotomous variable was replaced by LVEF as a con-
tinuous variable, which improved goodness of fit and dis-
crimination. When using GFR as continuous variable,
model performance did not improve. Comparing Models2 and 5, the AIC and C statistic did not improve, whereas
BIC was lower in Model 5.
Risk scores were derived for each individual patient
using the obtained the b-coefficients from final chosen
Model 5.
Table 3. Model Construction to Predict Mortality
Model 1 Model 2 Model 3 Model 4 Model 5
Variable b P Value b P Value b P Value b P Value b P Value
Age (per 10 years) 0.120 .356 0.138 .294 0.183 .160 — — — —
LVEF 25% 0.746 .007 — — — — — — — —
LVEF (per 5%)* — — 0.336 .001 0.334 .001 0.316 .001 0.323 .001
MI 0.595 .017 0.608 .015 0.603 .016 0.670 .007 0.656 .008
COPD 0.589 .053 0.605 .049 0.545 .076 0.595 .051 0.641 .035
CKD 0.903 .001 0.929 <.001 — — — — 0.992 <.001
GFR (per 15 mL/min)y — — — — 0.437 .005 0.474 .002 — —
Hyponatremia 1.018 .001 0.976 .002 1.005 .001 0.964 .002 0.941 .002
Anemia 0.456 .078 0.419 .104 0.460 .075 0.472 .067 0.427 .097
QRS 150 ms 0.672 .008 0.689 .007 0.649 .011 0.600 .018 0.660 .010
Parameter
Goodness of fit
Log LR chi-square 64.04 68.63 63.58 61.53 67.50
AIC 466 462 467 467 461
BIC 506 502 507 502 496
Discrimination
C statistic 0.749 0.754 0.737 0.736 0.756
*The b-coefficient represents the effect of LVEF associated with 5% change in patients with LVEF 35%. In patients with LVEF >35%, the score asso-
ciated with LVEF is 0.
yThe b-coefficient represents the effect of GFR associated with 15 mL/min change in patients with GFR <60 mL/min/1.73 m2.
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£ (COPD) + 0.992£ (CKD) + 0.941
£ (hyponatremia) + 0.427£ (anemia)
 0.660£ (QRS150),
where:LVEF = per 5% decrease of LVEF in patients with LVEF
35%. In patients with LVEF >35%, the score associated
with LVEF is 0;
CKD = estimated GFR <60 mL/min/1.73 m2, 1 if present,
otherwise 0;
Hyponatremia = serum level of sodium <136 mmol/L, 1 if
present, otherwise 0;Fig. 1. Mortality rates in the derivation cohorAnemia = serum level of hemoglobin <12 g/dL, 1 if pres-
ent, otherwise 0;
QRS150 =QRS duration150 ms, 1 if present, otherwise 0;
MI, COPD = 1 if present, otherwise 0.Subsequently, the derivation cohort was stratified by
ascending quintiles of the derived risk score (Suppl Table).
Mortality rates by quintiles of risk are presented in Fig. 1.
Mortality ranged from 2.8% (lowest quintile of risk score)
to 31.9% (highest quintile of risk score). Model discrimi-
nation as assessed by the C statistic was 0.76 (95% CI,
0.710.81).t stratified by quintiles of predicted risk.
Fig. 2. Calibration plot for derivation cohort (A) and validation cohort (B). Triangles represent quintiles of subjects grouped by similar
predicted risk. The distribution of subjects is indicated with spikes at the bottom of the graph, stratified by endpoint (death above the x-axis,
survivors below the x-axis).
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When the 3-year model was applied in the validation
cohort (N = 643 patients), the C statistic was 0.71 (95% CI,
0.650.76). In Fig. 2, calibration plots of the model are pre-
sented. The calibration-in-the-large was suboptimal, the pre-
diction model underestimated the risk in the derivation cohort
(A), whereas in the validation cohort (B) risk was overesti-
mated, which is reflected by a lower observed mortality
(44%) than predicted (50%). In the validation cohort, the cali-
bration slope was 0.90, which is acceptable indicating that the
predicted risks were not too extreme or too close to the base-
line risk. Based on the Brier score values, the model can be
considered as accurate as they fall below the 0.25 threshold.
Discussion
The present international, multicenter, retrospective cohort
study of 1282 HF patients demonstrates the feasibility of
using a risk score to predict early mortality in a real-world
population of CRT-D recipients. The risk score incorporates
MI, LVEF, QRS duration, COPD, CKD, hyponatremia, and
anemia. These variables are readily available and individu-
ally associated with a poor outcome.
In HF patients with reduced LVEF, NYHA class II, and
prolonged QRS duration, CRT improves clinical symptoms,
reduces hospitalizations, and lowers mortality in a consider-
able proportion of patients.5,19 Patients eligible for CRT
also qualify for defibrillator therapy as primary prevention
of sudden cardiac death. Consequently, implantation of a
CRT-D is part of the standard management of HF patientswith reduced LVEF and wide QRS. However, the benefit of
defibrillator therapy is not uniform and it remains to be
determined which patients benefit and whether patients do
not benefit from defibrillator therapy.
Better identification of patients who get the highest bene-
fit of the additional defibrillator therapy is desirable to
reduce unnecessary implantations and possible complica-
tions. Several previous studies have developed risk scores
to estimate mortality in ICD recipients.2024 A systematic
review and meta-analysis determined older age, poor base-
line renal function, history of COPD, diabetes mellitus,
peripheral vascular disease, decreased LVEF, and ICD
shocks during follow-up as strong predictors of mortality in
ICD patients.25 This meta-analysis provided the basis of a
novel prediction model, the HF Meta-score.26 The HF
Meta-score has been validated in the Ontario ICD database,
which included a mixed population of patients with primary
and secondary prevention indication treated with ICDs or
CRT-Ds and showed modest discrimination (C statistic
0.74). Some of the predictors in the HF Meta-score were
also identified in our study, eg, ischemic heart disease, poor
baseline renal function, COPD, and decreased LVEF. In the
current study, we did not compare the performance of our
risk estimation model with the HF Meta-score.
In a sub-analysis of the MADIT-II Trial, a risk score con-
sisting of 5 clinical risk factors (NYHA class >II, atrial
fibrillation, QRS duration >120 ms, age >70 years, and
urea >26 mg/dL) was developed to differentiate between
patients who would benefit from the ICD versus those who
would not.21 The MADIT-II risk score has recently been
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est discrimination (C statistic of 0.61 and 0.72).27,28 Of the
5 risk factors in the MADIT-II score, only poor baseline renal
function was a factor in our risk score. Risk factors as QRS
width>120 ms and NYHA>II mostly indicate CRT use.
The results of the present study are in line with those of
several previous studies, indicating that renal dysfunction
poses a strong and independent risk factor for overall mor-
tality despite CRT-D implantation and optimized medical
treatment of congestive heart failure. Besides renal dysfunc-
tion, we identified other clinical risk factors such as hypona-
tremia and anemia. Hyponatremia is a strong determinant of
long-term mortality in HF patients, irrespective of LVEF.29
Sharma et al30 investigated the prognostic implication of
hyponatremia in HF patients receiving CRT. Low baseline
serum levels of sodium were associated with poor progno-
sis. The results of our study confirm the association between
low serum levels of sodium and a higher mortality risk even
in a multivariate analysis.
The impact of baseline anemia on all-cause mortality in HF
patients with reduced LVEF has been evaluated in the HF-
ACTION trial.31 Over a median follow-up of 30 months,
anemia was associated with increased rates of death, hospital-
izations, and HF exacerbation. Venkateswaran et al32 exam-
ined the prognostic implication of anemia in CRT patients.
Baseline anemia and early post-implantation decline of hemo-
globin were associated with a worse 2-year prognosis. In our
study, baseline anemia was independently associated with
higher mortality.
Taken together, our results confirm that medically com-
plex HF patients, those with low LVEF, anemia, hyponatre-
mia, and comorbidities as COPD and CKD, have an
increased risk of mortality. This finding may be explained by
an increase in HF and non-arrhythmic mortality as the pres-
ence of these clinical variables suggests a more advanced HF
status. The decision whether to add ICD therapy must be
considered carefully in a shared decision-making process
with the patient taking into account riskbenefit tradeoffs
and life expectancy. In this context, Levy et al12 provided
compelling evidence of the heterogeneity of risk among pri-
mary prevention ICD patients by applying the SHFM to the
SCD-HeFT study cohort. The highest risk group had an
increased mortality with no benefit of ICD therapy despite
the greatest incidence of appropriate ICD shocks.Limitations
The current study has several limitations and these should
be viewed in its methodological context. First, the risk score
was not used to decide on implantation of a CRT-D. The
aim of study of the study was to calculate and validate a
risk score. Second, baseline heart rate, which is a known
predictor of mortality, had an excess of missing data and
was excluded from analysis. Unfortunately, the impact of
baseline heart rate in risk prediction within this model
remains unknown. Third, the study cohort included patients
over a 13-year period, during which guidelines for theimplantation of defibrillators and treatment of HF changed.
In the same period, the programming of devices with
respect to detection and treatment of ventricular arrhyth-
mias changed.Conclusion
A risk score based on routine, readily available clinical
variables can assist in identifying patients at high risk for
early mortality within 3 years after CRT-D implantation.Disclosures
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